EcoDrugPlus

Metabotropic Glutamate Receptor 2-Like

Ensembl ID : ENSCGOG00000004002
Gene Symbol: LOC115008644
3 Cross references
210 Possible Orthologues:

Metabotropic Glutamate Receptor 3-Like

Ensembl ID : ENSCGOG00000021521
Gene Symbol: LOC115009528
3 Cross references
212 Possible Orthologues:

Metabotropic Glutamate Receptor 5-Like

Ensembl ID : ENSCGOG00000011159
Gene Symbol: LOC115018921
3 Cross references
212 Possible Orthologues:

Methionine Aminopeptidase 2-Like

Ensembl ID : ENSCGOG00000022870
Gene Symbol: LOC115028313
3 Cross references
229 Possible Orthologues:

Microtubule-Associated Protein Tau-Like

Ensembl ID : ENSCGOG00000016670
Gene Symbol: LOC115025050
2 Cross references
205 Possible Orthologues:

Mitogen-Activated Protein Kinase 1

Ensembl ID : ENSCGOG00000024475
Gene Symbol: MAPK1
3 Cross references
213 Possible Orthologues:

Mitogen-Activated Protein Kinase 1-Like

Ensembl ID : ENSCGOG00000013077
Gene Symbol: LOC115012254
3 Cross references
198 Possible Orthologues:

Mitogen-Activated Protein Kinase 10

Ensembl ID : ENSCGOG00000010208
Gene Symbol: LOC115016627
3 Cross references
221 Possible Orthologues:

Mitogen-Activated Protein Kinase 11-Like

Ensembl ID : ENSCGOG00000014661
Gene Symbol: LOC115028365
3 Cross references
200 Possible Orthologues:

Mitogen-Activated Protein Kinase 14

Ensembl ID : ENSCGOG00000023949
Gene Symbol: MAPK14
3 Cross references
191 Possible Orthologues:

Mitogen-Activated Protein Kinase 14

Ensembl ID : ENSCGOG00000002573
Gene Symbol: MAPK14
3 Cross references
194 Possible Orthologues:

Mitogen-Activated Protein Kinase 8

Ensembl ID : ENSCGOG00000013828
Gene Symbol: LOC115024543
3 Cross references
223 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).